
Quarterly report 2023-Q1
added 05-10-2023
Syneos Health Cash Flow 2011-2026 | SYNH
Annual Cash Flow Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
450 M | 425 M | 318 M | 303 M | 198 M | 109 M | 205 M | 131 M | 37.3 M | 43 M | - |
Depreciation & Amortization |
236 M | 222 M | 242 M | 274 M | 180 M | 59.2 M | 56 M | 54.5 M | 58.5 M | 78.8 M | - |
Accounts Payables |
108 M | 114 M | 137 M | 98.6 M | 58.6 M | 23.7 M | 22.5 M | 16.5 M | - | - | - |
Accounts Receivables |
- | - | - | 729 M | - | 211 M | 158 M | 130 M | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
30.4 M | - | - | - | 70.9 M | - | - | - | 127 M | - | 311 M | 155 M | -38.6 M | - | 158 M | 83.5 M | -13.3 M | - | 191 M | 65.2 M | -47 M | - | 110 M | 98.4 M | 75.7 M | - | 95.1 M | 44.4 M | -646 K | - | 141 M | 95.3 M | 43.6 M | - | 117 M | 80.4 M | 31.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
61.6 M | - | - | - | 62.2 M | - | 17.7 M | 18.2 M | 57.9 M | - | 168 M | 112 M | 56.1 M | - | 182 M | 122 M | 61.2 M | - | 204 M | 136 M | 68 M | - | 96.6 M | 31.2 M | 15.6 M | - | 43.6 M | 14.5 M | 14.4 M | - | 13.8 M | 13.9 M | 14.2 M | - | 14.3 M | 11.3 M | 14.4 M | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
146 M | 119 M | - | - | 108 M | 108 M | 110 M | 108 M | 114 M | 114 M | 114 M | 114 M | 114 M | 137 M | 137 M | 137 M | 137 M | 98.6 M | 98.6 M | 98.6 M | 98.6 M | 58.6 M | 58.6 M | 58.6 M | 58.6 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 9.59 M | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
- | - | - | - | - | - | - | - | - | - | - | - | - | 782 M | 769 M | 776 M | 724 M | 729 M | 729 M | 729 M | 729 M | 643 M | 643 M | 643 M | 188 M | 211 M | 179 M | 190 M | 211 M | 158 M | 158 M | 158 M | 158 M | 130 M | 130 M | 130 M | 130 M | 130 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Syneos Health, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Agilent Technologies
A
|
$ 113.88 | -0.84 % | $ 34.6 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
$ 24.83 | 0.4 % | $ 690 M | ||
|
Danaher Corporation
DHR
|
$ 191.01 | -0.56 % | $ 136 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
- | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
$ 15.91 | -3.11 % | $ 481 M | ||
|
Guardant Health
GH
|
$ 93.3 | 4.06 % | $ 11.7 B | ||
|
CareDx, Inc
CDNA
|
$ 17.67 | -0.84 % | $ 942 M | ||
|
DexCom
DXCM
|
$ 63.11 | -0.16 % | $ 24.6 B | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
$ 107.16 | -2.24 % | $ 8.84 B | ||
|
Burning Rock Biotech Limited
BNR
|
$ 16.09 | -1.29 % | $ 173 M | ||
|
IQVIA Holdings
IQV
|
$ 170.62 | -0.01 % | $ 29.3 B | ||
|
Co-Diagnostics
CODX
|
$ 4.4 | 101.83 % | $ 5.85 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 269.17 | -1.93 % | $ 22.4 B | ||
|
Lantheus Holdings
LNTH
|
$ 78.08 | 2.89 % | $ 5.27 B | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
Medpace Holdings
MEDP
|
$ 508.52 | 2.52 % | $ 14.7 B | ||
|
Charles River Laboratories International
CRL
|
$ 169.54 | 0.78 % | $ 8.4 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
$ 1 270.0 | 0.27 % | $ 26.2 B | ||
|
Myriad Genetics
MYGN
|
$ 4.74 | 1.5 % | $ 439 M | ||
|
NeoGenomics
NEO
|
$ 8.06 | 0.5 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
$ 9.98 | 4.39 % | $ 2.16 B | ||
|
Natera
NTRA
|
$ 209.27 | 2.15 % | $ 20.6 B | ||
|
Biodesix
BDSX
|
$ 14.53 | -5.4 % | $ 1.88 B | ||
|
OpGen
OPGN
|
- | -16.95 % | $ 1.54 M | ||
|
Pacific Biosciences of California
PACB
|
$ 1.44 | 1.41 % | $ 432 M | ||
|
PerkinElmer
PKI
|
- | -0.91 % | $ 14.7 B | ||
|
Precipio
PRPO
|
$ 28.5 | 9.7 % | $ 45.7 M | ||
|
Personalis
PSNL
|
$ 6.17 | -6.23 % | $ 366 M | ||
|
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | ||
|
Illumina
ILMN
|
$ 126.44 | -1.02 % | $ 20.1 B | ||
|
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
$ 2.69 | 3.86 % | $ 87.3 K | ||
|
Biomerica
BMRA
|
$ 2.16 | -0.46 % | $ 4.96 M | ||
|
BioNano Genomics
BNGO
|
$ 1.17 | 1.74 % | $ 6.37 M | ||
|
Interpace Biosciences
IDXG
|
$ 2.0 | 1.27 % | $ 8.85 M |